SEC 13F Intelligence

Palo Alto Investors LP / ALXN

Palo Alto Investors LP’s Alexion Pharmaceuticals Inc Position

Does Palo Alto Investors LP own Alexion Pharmaceuticals Inc (ALXN)? Not currently — the last reported position was 94.8K shares worth $17M in Q2 2021; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$17M
Q2 2021
Shares
94.8K
% of Portfolio
+0.96%
Quarters Held
11
position exited

Position History ALXN

Reported value by quarter
Q4 ’18: $117MQ4 ’18Q1 ’19: $166MQ2 ’19: $134MQ2 ’19Q3 ’19: $94MQ4 ’19: $95MQ4 ’19Q1 ’20: $58MQ2 ’20: $50MQ2 ’20Q3 ’20: $52MQ4 ’20: $79MQ4 ’20Q1 ’21: $36MQ2 ’21: $17MQ2 ’21filingsflow.com
QuarterSharesValue% of Portfolio
Q2 202194.8K$17M+0.96%
Q1 2021235.3K$36M+2.05%
Q4 2020503.4K$79M+4.12%
Q3 2020457.5K$52M+2.87%
Q2 2020444.6K$50M+3.00%
Q1 2020642.5K$58M+4.83%
Q4 2019878.1K$95M+5.23%
Q3 2019958.0K$94M+6.25%
Q2 20191.02M$134M+6.52%
Q1 20191.23M$166M+6.93%
Q4 20181.20M$117M+6.24%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Palo Alto Investors LP’s full portfolio or all institutional holders of ALXN.